FDAnews Drug Daily Bulletin

LODH RAISES NOVARTIS TARGET TO CHF100

May 15, 2006
A A

Lombard Odier Darier Hentsch raised its target for Novartis (NVS) to CHF100 from CHF85. Says the new target is still a base case, not incorporating any early-stage pipeline drugs. "Currently, valuation does not reflect accelerating growth prospects for the Novartis flagship pharmaceuticals division," LODH says. "
Newratings